Cediranib is a potent oral inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases that functions as an anti-angiogenic agent. By blocking the signaling pathways responsible for… Read more
Cediranib is a potent oral inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases that functions as an anti-angiogenic agent. By blocking the signaling pathways responsible for new blood vessel formation, this small-molecule drug is investigated for its ability to restrict nutrient and oxygen supply to solid tumors, thereby inhibiting their growth. The category of Cediranib reference standards, including its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds, is essential for rigorous pharmaceutical analysis. Analytical laboratories rely on these high-quality compounds to perform impurity profiling, validate analytical methods, and ensure stringent quality control during drug development and manufacturing processes. These materials are critical for the accurate identification and quantification of degradation products and synthetic by-products, helping researchers maintain compliance with regulatory standards for drug safety and efficacy.